Clinical trial Recruiting at 1 site Observational Ages 2 to 16

Exploring muscle properties in children with spastic cerebral palsy

Official title: Botulinum Neurotoxin for Children With Cerebral Palsy: a Delicate Balance Between Clinical Benefits and Muscular Harm

Run by Universitaire Ziekenhuizen KU Leuven · NCT06991725 · Data updated 2026-11-12

This study is trying to see how the muscles of children with spastic cerebral palsy are different from those of kids without the condition, using special imaging techniques to look at things like muscle size and fat content.

Quick facts

Study typeObservational
Ages2 Years to 16 Years
SexAll
Enrollment51 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Locations1 site (Leuven, Vlaams-Brabant)
StatusRecruiting
StartedFebruary 3, 2025
Main results expectedDecember 2028
Study endsDecember 2028
Registry record updatedApril 29, 2026
Trial IDNCT06991725 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 2-16 years with a diagnosis of spastic cerebral palsy and specific motor function classifications.

Probably not a fit

Patients with dyskinesia, ataxia, or severe co-morbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the muscle composition and morphology in children diagnosed with spastic cerebral palsy (CP). Utilizing advanced imaging techniques such as quantitative Magnetic Resonance Imaging (qMRI) and shear wave elastography (SWE), the study will assess muscle fat infiltration, collagen content, and overall muscle size. By comparing these metrics in children with CP to typically developing peers, the research seeks to provide a comprehensive understanding of how muscle properties affect function in this population. The study will include children aged 2-16 years with varying degrees of CP severity, as classified by the Gross Motor Function Classification Scale (GMFCS).

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of muscle function in children with spastic cerebral palsy.

How similar studies have gone: While there is limited quantitative data on muscle composition in CP, the use of advanced imaging techniques like qMRI and SWE is promising and may provide novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
\- Children with spastic cerebral palsy

Inclusion criteria:

* Children (boys/girls) with congenital brain lesion, confirmed with neuro-imaging such as MRI
* At high-risk for CP or diagnosed spastic type of CP
* (Suspected) Gross Motor Function Classification Scale (GMFCS) Level I-III
* Uni or bilateral involvement
* Aged between 2-16 years

Exclusion criteria:

* Presence of dyskinesia or ataxia
* Severe co-morbidities (cognitive problems)
* BTX treatment in the gastrocnemius in the past 10 months
* Previous surgery at the investigated muscles.
* Previous orthopedic or neurosurgery
* Severe ankle deformities
* Weight for height values \>2SD or \<-2SD from mean

  * Typically developing children

Inclusion criteria:

• Aged between 2-16 years

Exclusion criteria:

* History of neurological, orthopedic or muscular problems
* Involvement in an elite or high-performance sporting program (Children performing the same sports for \> 5 hours/week will be excluded)

Where it's running

  • UZ Leuven
    Leuven, Vlaams-Brabant, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.